AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03404713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pathways to Health
Description: Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
Study NCT03404713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be4U
Description: This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
Study NCT03801343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrakos®
Description: Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes.
Study NCT01446978 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: 3 doses of hepatitis A vaccine, given at 0+1+6 months
Study NCT01446978 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
Study NCT02696460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: N2O/O2 analgesia
Description: Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
Study NCT02696460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/Prilocaine analgesia
Description: Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
Study NCT03306563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sample collection
Description: Samples of blood, urine and saliva will be collected at up to five successive time points.
Study NCT03306563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sample collection
Description: Samples of blood, urine and saliva will be collected at up to five successive time points.
Study NCT03306563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: Samples of blood, urine and saliva will be collected at up to five successive time points.
Study NCT00958100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir emtricitabine raltegravir
Description: switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
Study NCT00958100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Abacavir Raltegravir
Description: Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
Study NCT00958100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir free
Description: Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
Study NCT04346888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Injection (340 mg)
Description: HBM9161 Injection (340 mg)
Study NCT03414710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education booklet plus video plus brief counseling
Description: Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
Study NCT03414710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education booklet only
Description: Participants in the intervention group will only receive a health education booklet
Study NCT00385801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study NCT00385801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02765373 — intervention group
Intervention type: DRUG
Intervention: Exemestane
Study NCT02765373 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Study NCT02765373 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Study NCT02163915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets
Study NCT02163915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137 Placebo
Description: TAK-137 placebo-matching tablets
Study NCT00208767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan was titrated to a target dose of 320 mg orally daily
Study NCT00208767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill will be given orally daily.
Study NCT01393912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Crenolanib
Description: Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
Study NCT05442463 — intervention group
Intervention type: DRUG
Intervention: Captopril Tablets
Description: Captorpril challenge to each participant
Study NCT03663218 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Dose escalation
Description: This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
Study NCT01805921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given intra-nasally (high dose)
Description: High dose = 5x10\^10 vp
Study NCT03685799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pathological revision
Description: Pathological revision
Study NCT02939144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquorice
Description: Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
Study NCT00321100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
Study NCT00321100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
Study NCT02192359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carboxylesterase-expressing Allogeneic Neural Stem Cells
Description: Given intracranially
Study NCT02192359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT02192359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04813055 — intervention group
Intervention type: PROCEDURE
Intervention: Therapeutic EUS
Description: 1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~6. EUS-guided pancreatic duct drainage
Study NCT04813055 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Procedures
Description: Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
Study NCT04813055 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Interventions
Description: Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
Study NCT04813055 — intervention group
Intervention type: PROCEDURE
Intervention: non-EUS-based endoscopic procedures
Description: Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
Study NCT02898038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES PARIS
Description: AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
Study NCT02192359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02192359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01716702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Prostate Cancer Support Group
Description: The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).
Study NCT04211883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTIVE intervention
Description: The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
Study NCT00536185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
Study NCT00536185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
Study NCT05091359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste
Description: Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
Study NCT03006107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraligamentary injection piroxicam
Description: intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone
Study NCT03006107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraligamentary mepevacaine
Description: mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
Study NCT02845934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
Study NCT02888340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
Study NCT02685410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Night Stan Prototype
Description: The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
Study NCT01869517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intrastromal corneal ring segments (Keraring) implantation
Study NCT01869517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrastromal corneal continuous ring (Myoring) implantation
Study NCT04253262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib (PO twice daily continuous)
Study NCT04253262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)
Study NCT00321100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 IV day 1 every 21 days
Study NCT00321100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
Study NCT03556774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'WeChat WeQuit' smoking cessation training program
Description: Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
Study NCT00453063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: 50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
Study NCT00453063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sprays in each nostril once daily in the morning
Study NCT01586065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: CGM during 24-hr CRC stay.
Study NCT00114530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mHSCT
Description: Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
Study NCT01805921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (high dose)
Description: High dose = 1x10\^8 pfu
Study NCT00114530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
Study NCT03949036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid fluid administration with the target of stroke volume variation ≤ 12%
Description: The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
Study NCT03949036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystalloid fluid administration with the target of stroke volume variation ≤ 6%
Description: The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
Study NCT03572972 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Treatment for NVAF patients
Study NCT06565299 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiovascular surgery with cardiopulmonary bypass
Description: Cardiovascular surgery about congenital heart defects with cardiopulmonary bypass
Study NCT01805921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (high dose)
Description: High dose = 5x10\^10 vp
Study NCT01805921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given intranasally (low dose)
Description: Low dose = 5x10\^9 vp
Study NCT01805921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (low dose)
Description: Low dose = 1x10\^7 pfu
Study NCT01805921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (low dose)
Description: Low dose = 5x10\^9 vp
Study NCT03860220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEWSTATIN TS
Description: Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
Study NCT00689884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
Study NCT04035031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga 10mg
Description: Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
Study NCT04035031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
Study NCT01221116 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: levosimendan
Description: levosimendan 0.1 microgram/kg/min) for 24 hours
Study NCT04013178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accentuated eccentric loading + electromyostimulation
Description: An innovative training intervention to optimize muscle strength and muscle mass
Study NCT04013178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resistance training
Description: A conventional approach to resistance training
Study NCT02076711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprololsuccinate
Study NCT03860220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CADUET
Description: Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
Study NCT03342651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin D
Description: Vitamin D, general anesthesia, respiratory complications
Study NCT02061332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 Pulsed Dendritic cell Vaccine
Description: 6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
Study NCT00907218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline (Chantix)
Description: Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.